Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rocket Pharmaceuticals (RCKT) Cash & Equivalents: 2016-2024

Historic Cash & Equivalents for Rocket Pharmaceuticals (RCKT) over the last 9 years, with Dec 2024 value amounting to $163.6 million.

  • Rocket Pharmaceuticals' Cash & Equivalents fell 5.47% to $222.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $222.8 million, marking a year-over-year decrease of 5.47%. This contributed to the annual value of $163.6 million for FY2024, which is 192.71% up from last year.
  • Rocket Pharmaceuticals' Cash & Equivalents amounted to $163.6 million in FY2024, which was up 192.71% from $55.9 million recorded in FY2023.
  • Rocket Pharmaceuticals' Cash & Equivalents' 5-year high stood at $335.9 million during FY2020, with a 5-year trough of $55.9 million in FY2023.
  • For the 3-year period, Rocket Pharmaceuticals' Cash & Equivalents averaged around $120.0 million, with its median value being $140.5 million (2022).
  • In the last 5 years, Rocket Pharmaceuticals' Cash & Equivalents slumped by 60.22% in 2023 and then soared by 192.71% in 2024.
  • Yearly analysis of 5 years shows Rocket Pharmaceuticals' Cash & Equivalents stood at $335.9 million in 2020, then slumped by 30.73% to $232.7 million in 2021, then crashed by 39.61% to $140.5 million in 2022, then slumped by 60.22% to $55.9 million in 2023, then spiked by 192.71% to $163.6 million in 2024.